{"title":"Spot Scanning Proton Beam Therapy for Surgery-inaccessible Hepatocellular Carcinoma: Preliminary Results.","authors":"Yutaka Fujimoto, Sachika Shiraishi, Masashi Yamanaka, Akihiro Yamano, Kazuki Matsumoto, Shintaro Shiba, Toshitaka Tsukiyama, Masahiro Kobayashi, Koichi Tokuuye","doi":"10.21873/invivo.13966","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Spot scanning proton beam therapy (SS-PBT) was employed for the treatment of surgery-inaccessible hepatocellular carcinoma, primarily influenced by respiratory movement.</p><p><strong>Patients and methods: </strong>Between October 2022 and December 2023, 12 patients were enrolled in this study to evaluate the efficacy of SS-PBT. The median follow-up time was 13.1 months.</p><p><strong>Results: </strong>The one-year survival, progression-free survival, and local control rates were 79.5%, 57.1%, and 100%, respectively, without grade 2 or higher PBT-related toxicities. The clinical outcomes of these 12 patients appear comparable to data from prospective studies conducted at proton centers across Japan.</p><p><strong>Conclusion: </strong>SS-PBT shows promise as a treatment option for surgery-inaccessible hepatocellular carcinoma.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 3","pages":"1654-1660"},"PeriodicalIF":1.8000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12042008/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13966","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Spot scanning proton beam therapy (SS-PBT) was employed for the treatment of surgery-inaccessible hepatocellular carcinoma, primarily influenced by respiratory movement.
Patients and methods: Between October 2022 and December 2023, 12 patients were enrolled in this study to evaluate the efficacy of SS-PBT. The median follow-up time was 13.1 months.
Results: The one-year survival, progression-free survival, and local control rates were 79.5%, 57.1%, and 100%, respectively, without grade 2 or higher PBT-related toxicities. The clinical outcomes of these 12 patients appear comparable to data from prospective studies conducted at proton centers across Japan.
Conclusion: SS-PBT shows promise as a treatment option for surgery-inaccessible hepatocellular carcinoma.
期刊介绍：
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
